Rearrangements involving NF1 and NF2 have been reported in other cancers and have been associated with therapeutic resistance in HGSOC (53, 37) but have not been previously identified in ovarian endometrioid carcinoma. This evidence concerns the gene NF1 and ovarian endometrioid carcinoma.